Intravesical therapy for bladder cancer

Urology

Volumn 55, Issue 2, 2000, Pages 161-168

  Kamat, Ashish M ^a   Lamm, Donald L ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BROPIRIMINE; DOXORUBICIN; EPIRUBICIN; INTERFERON; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN C; THIOTEPA; VALRUBICIN;

BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DRUG INDUCED DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; HUMANS; PHOTOCHEMOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 0033980503     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00463-X     Document Type: Review

References (64)

1. Cohen S.M., Johansson S.L. Epidemiology and etiology of bladder cancer. Urol Clin North Am. 19:1992;421-428.
2. Ratliff T.L., Gillen D.P., Catalona W.J. Requirement of thymus dependent immune response for BCG mediated antitumor activity. J Urol. 137:1987;155-159.
3. Jansson O.T., Morcos E., Brundin L., et al. The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br J Cancer. 78:1998;588-592.
4. Lamm D.L. Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol. 134:1985;40-47.
5. Herr H.W., Pinsky C.M., Whitmore W.F. Jr, et al. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors. Urology. 25:1985;119-123.
6. Herr H.W. Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin North Am. 18:1991;525-528.
7. Pagano F., Bassi P., Milani C., et al. Low dose BCG regimen in superficial bladder cancer therapy is it effective? J Urol. 146:1991;32-35.
8. Melekos M.D., Chionis H., Pantazakos A., et al. Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer results of a controlled prospective trial with modified treatment schedule . J Urol. 149:1993;744-748.
9. Krege S., Giani G., Meyer R., et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin . J Urol. 156:1996;962-966.
10. Herr H.W., Laudone V.P., Badalament R.A., et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 6:1988;1450-1455.
11. Lamm D.L. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 19:1982;573-580.
12. De Jager R., Guinan P., Lamm D., et al. Long term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette Guérin - overview analysis of six phase II clinical trials. Urology. 38:1991;507-514.
13. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209.
14. Lamm D.L. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology. 9:1995;947-952. (Huntingt).
15. Orsola A., Palou J., Xavier B., et al. Primary bladder carcinoma in situ assessment of early BCG response as a prognostic factor . Eur Urol. 33:1998;457-463.
16. Rosenbaum R.S., Park M.C., Fleischmann J. Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer. Urology. 47:1996;208-211.
17. Badalament R.A., Herr H.W., Wong G.Y., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol. 5:1987;441-447.
18. Kavoussi L.R., Torrence R.J., Gillen D.P., et al. Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J Urol. 139:1988;935-940.
19. Lamm D.L., Blumenstein B., Sarsody M., et al. Significant long-term patient benefits with BCG maintenance therapy a South West Oncology Group study . J Urol. 157:1997;213-216.
20. Lamm D.L., Riggs D.R., Shriver J.S., et al. Megadose vitamins in bladder cancer a double-blind clinical trial . J Urol. 151:1994;21-26.
21. Lamm D.L., van der Meijden A.P.M., Morales A., et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol. 147:1992;596-600.
22. De Boer E.C., Steerenberg P.A., van der Meijden A.P.M., et al. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol. 148:1992;1577-1582.
23. DeHaven J.I., Traynelis C., Riggs D.R., et al. Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guérin toxicity. J Urol. 147:1992;738-742.
24. Bohle A., Schuller J., Knipper A., et al. Bacillus Calmette-Guérin treatment and vesicorenal reflux. Eur Urol. 17:1990;125-128.
25. Glashan R. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J Urol. 144:1990;658-672.
26. Torti F.M., Shortliffe L.D., Williams R.D., et al. Alpha-interferon in superficial bladder cancer a northern California oncology group study . J Clin Oncol. 6:1988;476-483.
27. Belldegrun A.S., Franklin J.R., O'Donnell M.A., et al. Superficial bladder cancer the role of interferon-alpha . J Urol. 159:1998;1793-1801.
28. Lamm D.L., Morales A., Grossman H.B., et al. Keyhole limpet hemocyanin (KLH) immunotherapy of papillary and in situ transitional cell carcinoma of the bladder. A multicenter phase I-II clinical trial. J Urol. 155:1996;A1405.
29. Jurincic C.D., Engelmann U., Gasch J., et al. Immunotherapy in bladder cancer with keyhole limpet hemocyanin a randomized study . J Urol. 139:1988;723-726.
30. Flamm J., Bucher A., Höltl W., et al. Recurrent superficial transitional cell carcinoma of the bladder adjuvant topical chemotherapy versus immunotherapy: a prospective randomized trial . J Urol. 144:1990;260-263.
31. Sarosdy M.F., Lowe B.A., Schellhammer P.F., et al. Bropirimine immunotherapy of carcinoma in situ of the bladder results of a phase II trial . Urology. 48:1996;21-27.
32. Lamm D.L., Griffith J.G. Intravesical therapy does it affect the natural history of bladder cancer? Semin Urol. 10:1992;39-44.
33. Walker M.C., Masstera J.R., Parris C.N., et al. Intravesical chemotherapy in vitro studies on the relationship between dose and cytotoxicity. Urol Res. 14:1987;137-140.
34. Wientjes M.G., Dalton J.T., Badalament R.A., et al. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res. 51:1991;4347-4354.
35. Solsona E., Iborra I., Ricos J.V., et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer short and long-term followup . J Urol. 161:1999;1120-1123.
36. Huland H., Klöppel G., Feddersen I., et al. Comparison of different schedules of cystostatic intravesical instillations in patients with superficial bladder carcinoma final evaluation of a prospective multicenter study with 419 patients . J Urol. 144:1990;68-75.
37. Lamm DL: Clinical evaluation of immunotherapy. Cancer Surv 31: 99-108, 1998.
38. Kim H.H., Lee C. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol. 139:1988;245A.
39. Thrasher J.B., Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am. 19:1992;529-539.
40. Zincke H., Utz D.C., Taylor W.F., et al. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence a prospective, randomized, double blind, controlled trial . J Urol. 129:1983;505-508.
41. Kamat A.M., DeHaven J.I., Lamm D.L. Quinolone antibiotics a potential adjunct to intravesical chemotherapy for bladder cancer . Urology. 54:1999;56-61.
42. Rajala P., Liukkonen T., Raitanen M., et al. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer a prospective randomized multicenter study Finnbladder III . J Urol. 161:1999;1133-1135.
43. Okamura K., Kinukawa T., Tsumura Y., et al. A randomized study of short- versus long-term intravesical epirubicin instillation for superficial bladder cancer. Eur Urol. 33:1998;285-288.
44. Greenberg R.E., Bahnson R.R., Wood D., et al. Initial report on intravesical administration of N- trifluoroacetyl adriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 49:1997;471-475.
45. Bahnson R., Brosman S., Dalkin B., et al. Effectiveness of valrubicin in patients with BCG-refractory carcinoma in situ of the bladder. J Urol. 161:1999;171.
46. Nseyo U.O. Photodynamic therapy. Urol Clin North Am. 19:1992;591-599.
47. Nseyo U.O., DeHaven J., Dougherty T.J., et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer a long-term experience . J Clin Laser Med Surg. 16:1988;61-68.
48. Oosterlinck W., Kurth K.H., Schröder F., et al. A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single state Ta, T1 papillary carcinoma of the bladder. J Urol. 149:1993;749-752.
49. Abel P.D. Follow-up of patients with "superficial" transitional cell carcinoma of the bladder the case for a change in policy . Br J Urol. 72:1993;135-142.
50. Bostwick D.G. Natural history of bladder cancer. J Cell Biochem. 161:1991;31-38.
51. Messing EM, Young TB, Hunt VB, et al: Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45: 387-396, 1995.
52. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours 15-year outcome . Br J Urol. 80:1997;762-765.
53. Vicente J., Laguna M.P., Duarte D., et al. Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours. Br J Urol. 68:1991;380-382.
54. Obek C., Shelfo S.W., Korman H.J., et al. Intravesical therapy for transitional cell carcinoma of the bladder the community practice . Urology. 53:1999;82-87.
55. Lamm D.L., Torti F.M. Bladder cancer, 1996. CA Cancer J Clin. 46:1996;93-112.
56. Prout G.R. Jr, Koontz W.W. Jr, Coombs L.J., et al. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol. 130:1983;677-680.
57. Akaza H., Koiso K., Kotake T., et al. Long term results of intravesical chemoprophylaxis of superficial bladder cancer experience of the Japanese Urological Cancer Research Group for Adriamycin . Cancer Chemother Pharmacol. 30:1992;15-19.
58. Kurth K.H., Debruyne F.J.M., Senge T., et al. Adjuvant chemotherapy of superficial transitional cell carcinoma an E.O.R.T.C. randomized trial comparing doxorubicin hydrochloride, ethoglucid, and TUR alone . Schröder F.H., Richards B. EORTC Genitourinary Group Monograph 2, Part B Superficial Bladder Tumors . 1985;135-142 Alan R Liss, New York.
59. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of EORTC/MRC randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol. 156:1996;1934-1940.
60. Lamm D.L., Riggs D.R., Traynelis C.L., et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol. 153:1995;1444-1450.
61. Melekos M.D., Chionis H.A., Paranychianakis G.S., et al. Intravesical 4′-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. Cancer. 72:1993;1749-1755.
62. Cookson M.S., Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol. 148:1992;797-801.
63. Klein E.A., Rogatko A., Herr H.W. Management of local bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol. 147:1992;601-605.
64. Okuno H., Kakehi Y., Ozdemir E., et al. Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers. J Urol. 158:1997;1996-1999.